You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCiclesonide
Accession NumberDB01410
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionCiclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • BI54903
  • RPR-251526
  • RPR251526
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlvescoAerosol, metered100 mcgRespiratory (inhalation)Takeda Canada Inc2006-09-27Not applicableCanada
AlvescoAerosol, metered80 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2009-02-19Not applicableUs
AlvescoAerosol, metered80 ug/1Respiratory (inhalation)Sunovion Pharmaceuticals Inc.2008-10-01Not applicableUs
AlvescoAerosol, metered200 mcgRespiratory (inhalation)Takeda Canada Inc2006-09-27Not applicableCanada
AlvescoAerosol, metered160 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2009-02-23Not applicableUs
AlvescoAerosol, metered160 ug/1Respiratory (inhalation)Sunovion Pharmaceuticals Inc.2008-10-01Not applicableUs
AlvescoAerosol, metered50 mcgRespiratory (inhalation)Takeda Canada IncNot applicableNot applicableCanada
OmnarisSpray50 ug/1NasalREMEDYREPACK INC.2013-07-16Not applicableUs
OmnarisSpray, metered50 mcgNasalTakeda Canada Inc2008-04-10Not applicableCanada
OmnarisSpray50 ug/1NasalSunovion Pharmaceuticals Inc.2008-03-01Not applicableUs
OmnarisSpray50 ug/1NasalPhysicians Total Care, Inc.2009-04-15Not applicableUs
Omnaris HFAAerosol, metered50 mcgNasalTakeda Canada Inc2013-08-07Not applicableCanada
ZetonnaAerosol, metered37 ug/1NasalSunovion Pharmaceuticals Inc.2012-07-30Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ciclesonideSpray, metered50 mcgNasalApotex Inc2016-11-25Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OmniairNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS59502J185
CAS number126544-47-6
WeightAverage: 540.697
Monoisotopic: 540.308703757
Chemical FormulaC32H44O7
InChI KeyLUKZNWIVRBCLON-GXOBDPJESA-N
InChI
InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1
IUPAC Name
2-[(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-9,13-dimethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-8-yl]-2-oxoethyl 2-methylpropanoate
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(O[C@@H](O2)C1CCCCC1)C(=O)COC(=O)C(C)C
Pharmacology
IndicationFor the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Structured Indications
PharmacodynamicsCiclesonide is a pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120 times higher than the parent compound. The precise mechanism through which ciclesonide affects allergic rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic inflammation.
Mechanism of actionGlucocorticoids such as ciclesonide can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Ciclesonide reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Ciclesonide is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
agonist
HumanP04150 details
Related Articles
AbsorptionCiclesonide and des-ciclesonide have negligible oral bioavailability (both less than 1%) due to low gastrointestinal absorption and high first-pass metabolism. The intranasal administration of ciclesonide at recommended doses results in negligible serum concentrations of ciclesonide.
Volume of distributionNot Available
Protein bindingThe percentage of ciclesonide and des-ciclesonide bound to human plasma proteins averaged ≥ 99% each, with ≤ 1% of unbound drug detected in the systemic circulation.
Metabolism

Des-ciclesonide undergoes metabolism in the liver to additional metabolites mainly by the cytochrome P450 (CYP) 3A4 isozyme and to a lesser extent by CYP 2D6.

Route of eliminationNot Available
Half lifeNot Available
Clearance
  • 152 L/hr [Following IV administration of 800 mcg of ciclesonide]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ciclesonide.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Ciclesonide.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ciclesonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Ciclesonide.Approved
AldesleukinCiclesonide may decrease the antineoplastic activities of Aldesleukin.Approved
ALT-110The risk or severity of adverse effects can be increased when Ciclesonide is combined with ALT-110.Investigational
Aluminum hydroxideThe bioavailability of Ciclesonide can be decreased when combined with Aluminum hydroxide.Approved
Aluminum phosphateThe bioavailability of Ciclesonide can be decreased when combined with Aluminum phosphate.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ciclesonide.Approved
AmiodaroneThe metabolism of Ciclesonide can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BCiclesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Ciclesonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Ciclesonide.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Ciclesonide.Approved, Investigational
AprepitantThe serum concentration of Ciclesonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Ciclesonide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ciclesonide can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Ciclesonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ciclesonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Ciclesonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Ciclesonide.Approved, Investigational
BazedoxifeneThe serum concentration of Ciclesonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideCiclesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ciclesonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Ciclesonide.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ciclesonide.Investigational
BexaroteneThe serum concentration of Ciclesonide can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Ciclesonide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe metabolism of Ciclesonide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ciclesonide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ciclesonide can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Ciclesonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Ciclesonide.Investigational
BumetanideCiclesonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Ciclesonide.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Ciclesonide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe metabolism of Ciclesonide can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Ciclesonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Ciclesonide.Experimental
CDX-110The risk or severity of adverse effects can be increased when Ciclesonide is combined with CDX-110.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ciclesonide.Approved, Investigational
CeritinibThe serum concentration of Ciclesonide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Ciclesonide.Approved, Vet Approved
ChlorothiazideCiclesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Ciclesonide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneCiclesonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe metabolism of Ciclesonide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ciclesonide can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Ciclesonide.Approved
ClotrimazoleThe metabolism of Ciclesonide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Ciclesonide can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ciclesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Ciclesonide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Ciclesonide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Ciclesonide.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Ciclesonide can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Ciclesonide.Investigational
CyclosporineThe metabolism of Ciclesonide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Ciclesonide.Investigational
DabrafenibThe serum concentration of Ciclesonide can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe metabolism of Ciclesonide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ciclesonide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Ciclesonide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ciclesonide can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Ciclesonide.Investigational
DexamethasoneThe serum concentration of Ciclesonide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DichlorvosThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ciclesonide.Approved, Vet Approved
DienestrolThe serum concentration of Ciclesonide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Ciclesonide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Ciclesonide.Approved
DihydroergotamineThe metabolism of Ciclesonide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneCiclesonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Ciclesonide can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Donepezil.Approved
DoxycyclineThe metabolism of Ciclesonide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ciclesonide can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Ciclesonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Ciclesonide.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Ciclesonide.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Ciclesonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Ciclesonide can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Ciclesonide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Ciclesonide.Approved
ErythromycinThe metabolism of Ciclesonide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ciclesonide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Ciclesonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Ciclesonide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Ciclesonide can be increased when it is combined with Estrone.Approved
Etacrynic acidCiclesonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Ciclesonide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ciclesonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Ciclesonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Ciclesonide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Ciclesonide.Approved, Investigational
EtravirineThe serum concentration of Ciclesonide can be decreased when it is combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Ciclesonide.Approved
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Ciclesonide.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Ciclesonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Ciclesonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Fenthion.Vet Approved
FleroxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ciclesonide.Approved, Withdrawn
FluconazoleThe metabolism of Ciclesonide can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Ciclesonide.Vet Approved
FluoxymesteroneCiclesonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ciclesonide.Approved, Investigational
FluvoxamineThe metabolism of Ciclesonide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ciclesonide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ciclesonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ciclesonide can be increased when combined with Fosphenytoin.Approved
FurosemideCiclesonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Ciclesonide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Ciclesonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Ciclesonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Ciclesonide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Ciclesonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Ciclesonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Ciclesonide.Investigational
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Ciclesonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Ciclesonide.Approved, Investigational
HydrochlorothiazideCiclesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideCiclesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Ciclesonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Ciclesonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Ciclesonide.Approved
IdelalisibThe serum concentration of Ciclesonide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ciclesonide can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Ciclesonide.Approved
IndapamideCiclesonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Ciclesonide can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Ciclesonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Ciclesonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Ciclesonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Ciclesonide is combined with INGN 225.Investigational
IsavuconazoniumThe metabolism of Ciclesonide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Ciclesonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ciclesonide.Withdrawn
IsradipineThe metabolism of Ciclesonide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ciclesonide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ciclesonide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Ciclesonide.Experimental
KetoconazoleThe metabolism of Ciclesonide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Ciclesonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ciclesonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Ciclesonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Ciclesonide.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Ciclesonide can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Ciclesonide.Approved
LovastatinThe metabolism of Ciclesonide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ciclesonide.Approved
LuliconazoleThe serum concentration of Ciclesonide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ciclesonide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ciclesonide.Approved, Investigational
MagaldrateThe bioavailability of Ciclesonide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Ciclesonide can be decreased when combined with Magnesium carbonate.Approved
Magnesium hydroxideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Ciclesonide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Ciclesonide.Approved
Magnesium TrisilicateThe bioavailability of Ciclesonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Ciclesonide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ciclesonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ciclesonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Ciclesonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Ciclesonide.Approved
MestranolThe serum concentration of Ciclesonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Ciclesonide.Withdrawn
MethallenestrilThe serum concentration of Ciclesonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideCiclesonide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneCiclesonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneCiclesonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Ciclesonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Ciclesonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Ciclesonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Ciclesonide.Investigational
ModafinilThe serum concentration of Ciclesonide can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ciclesonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Ciclesonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Ciclesonide.Investigational
NafcillinThe serum concentration of Ciclesonide can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Ciclesonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Ciclesonide.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Ciclesonide.Investigational
NefazodoneThe metabolism of Ciclesonide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ciclesonide can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Ciclesonide.Approved
NetupitantThe serum concentration of Ciclesonide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ciclesonide can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ciclesonide.Approved
NilotinibThe metabolism of Ciclesonide can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ciclesonide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ciclesonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ofloxacin.Approved
OlaparibThe metabolism of Ciclesonide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ciclesonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ciclesonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Ciclesonide.Vet Approved
OsimertinibThe serum concentration of Ciclesonide can be increased when it is combined with Osimertinib.Approved
OxandroloneCiclesonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ciclesonide.Approved
OxymetholoneCiclesonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ciclesonide.Withdrawn
PalbociclibThe serum concentration of Ciclesonide can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Ciclesonide.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Ciclesonide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Ciclesonide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Ciclesonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ciclesonide.Approved, Vet Approved
PhenytoinThe metabolism of Ciclesonide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ciclesonide.Approved, Investigational
PiretanideCiclesonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Ciclesonide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Ciclesonide.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Ciclesonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideCiclesonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Ciclesonide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Ciclesonide can be increased when combined with Primidone.Approved, Vet Approved
PromestrieneThe serum concentration of Ciclesonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Ciclesonide.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Ciclesonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Ciclesonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneCiclesonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rabies vaccine.Approved
RanolazineThe metabolism of Ciclesonide can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Ciclesonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Ciclesonide.Experimental, Investigational
RifabutinThe metabolism of Ciclesonide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ciclesonide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ciclesonide can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Ciclesonide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Ciclesonide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rosoxacin.Approved
S EquolThe serum concentration of Ciclesonide can be increased when it is combined with S Equol.Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ciclesonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Ciclesonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Ciclesonide.Approved
SaquinavirThe metabolism of Ciclesonide can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Ciclesonide can be increased when it is combined with Secoisolariciresinol.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Ciclesonide.Approved, Investigational
SildenafilThe metabolism of Ciclesonide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ciclesonide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ciclesonide can be increased when it is combined with Simeprevir.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Ciclesonide.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Ciclesonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Ciclesonide.Investigational
St. John's WortThe serum concentration of Ciclesonide can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololCiclesonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Ciclesonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ciclesonide.Approved
SulfisoxazoleThe metabolism of Ciclesonide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Ciclesonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Ciclesonide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Ciclesonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Ciclesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Ciclesonide.Approved
TelithromycinThe metabolism of Ciclesonide can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Ciclesonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Ciclesonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Ciclesonide.Approved
TestosteroneCiclesonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Ciclesonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ciclesonide.Approved
TiboloneThe serum concentration of Ciclesonide can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Ciclesonide can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Ciclesonide.Investigational
TocilizumabThe serum concentration of Ciclesonide can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ciclesonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Ciclesonide.Approved
TorasemideCiclesonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Ciclesonide.Approved, Investigational
TrichlorfonThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideCiclesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ciclesonide.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Ciclesonide.Investigational, Withdrawn
VenlafaxineThe metabolism of Ciclesonide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ciclesonide can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Ciclesonide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinCiclesonide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ciclesonide.Approved
ZeranolThe serum concentration of Ciclesonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Ciclesonide.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ciclesonide can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Ciclesonide.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Beate Schmidt, “Process for preparing crystalline ciclesonide with defined particle size.” U.S. Patent US20060128954, issued June 15, 2006.

US20060128954
General References
  1. Mutch E, Nave R, McCracken N, Zech K, Williams FM: The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007 May 15;73(10):1657-64. Epub 2007 Jan 28. [PubMed:17331475 ]
External Links
ATC CodesR03BA08R01AD13
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.9439
Caco-2 permeable-0.6847
P-glycoprotein substrateSubstrate0.7787
P-glycoprotein inhibitor IInhibitor0.8247
P-glycoprotein inhibitor IIInhibitor0.9476
Renal organic cation transporterNon-inhibitor0.7744
CYP450 2C9 substrateNon-substrate0.8232
CYP450 2D6 substrateNon-substrate0.915
CYP450 3A4 substrateSubstrate0.774
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.7104
CYP450 2D6 inhibitorNon-inhibitor0.9407
CYP450 2C19 inhibitorNon-inhibitor0.9151
CYP450 3A4 inhibitorNon-inhibitor0.6192
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8478
Ames testNon AMES toxic0.9032
CarcinogenicityNon-carcinogens0.9367
BiodegradationNot ready biodegradable0.9897
Rat acute toxicity3.5547 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9738
hERG inhibition (predictor II)Non-inhibitor0.595
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)100 mcg
Aerosol, meteredRespiratory (inhalation)160 ug/1
Aerosol, meteredRespiratory (inhalation)200 mcg
Aerosol, meteredRespiratory (inhalation)50 mcg
Aerosol, meteredRespiratory (inhalation)80 ug/1
SprayNasal50 ug/1
Spray, meteredNasal50 mcg
Aerosol, meteredNasal50 mcg
Aerosol, meteredNasal37 ug/1
Prices
Unit descriptionCostUnit
Alvesco 160 mcg/act Aerosol 6.1 gm Inhaler162.24USD inhaler
Alvesco 80 mcg/act Aerosol 6.1 gm Inhaler162.24USD inhaler
Alvesco 160 mcg inhaler31.1USD g
Alvesco 80 mcg inhaler31.1USD g
Omnaris 50 mcg nasal spray11.01USD g
Alvesco 200 mcg/dose Metered Dose Aerosol0.66USD dose
Alvesco 100 mcg/dose Metered Dose Aerosol0.4USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2050812 No2003-07-292011-09-06Canada
CA2388325 No2007-09-182020-10-20Canada
US5482934 No1997-10-242017-10-24Us
US5695743 No1993-07-062010-07-06Us
US5775321 No1995-07-072015-07-07Us
US6006745 No1996-12-282016-12-28Us
US6120752 No1998-05-132018-05-13Us
US6264923 No1998-05-132018-05-13Us
US6767901 No2000-10-212020-10-21Us
US6939559 No1999-04-212019-04-21Us
US7235247 No1999-04-212019-04-21Us
US8371292 No2008-02-012028-02-01Us
US8383611 No2000-10-202020-10-20Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00157 mg/mLALOGPS
logP4.08ALOGPS
logP5.32ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)14.78ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.13 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity146.28 m3·mol-1ChemAxon
Polarizability60.18 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Meta-dioxolane
  • Cyclic alcohol
  • Carboxylic acid ester
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Acetal
  • Carboxylic acid derivative
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carbonyl group
  • Organic oxide
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Organooxygen compound
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Barnes NC: The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J. 2007 Jun;16(3):149-54. [PubMed:17530144 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Peet CF, Enos T, Nave R, Zech K, Hall M: Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86. [PubMed:16435573 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Mutch E, Nave R, McCracken N, Zech K, Williams FM: The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007 May 15;73(10):1657-64. Epub 2007 Jan 28. [PubMed:17331475 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on July 17, 2007 06:38 / Updated on December 07, 2016 02:38